Author

Kent Iverson

Observed names: Iverson, Kent, K. A. Iverson, K. Iverson

Observed institutions: University of Manchester, Acumen Pharmaceuticals (United States)

OpenAlex ID: A5111687574

ACU193, a Monoclonal Antibody that Selectively Binds Soluble Aβ Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan

2022 · Eric Siemers, J. Hitchcock, et al. · The Journal of Prevention of Alzheimer s Disease · 26

O2–06–03: ACU‐193: A candidate therapeutic antibody that selectively targets soluble beta‐amyloid oligomers

2013 · Grant Krafft, Franz Hefti, et al. · Alzheimer s & Dementia · 11

Analytical comparability demonstrated for an IgG4 molecule, inclacumab, following transfer of manufacturing responsibility from Roche to Global Blood Therapeutics

2022 · Radu Mihaila, Dipali Ruhela, et al. · Expert Opinion on Biological Therapy · 5

GLP-1R agonists are not a quick fix for weight loss

2012 · K. A. Iverson · BMJ · 2

Works count: 5

Citation count: 44

H-index: 3

I10-index: 2